PEPG

3.7803.82%
JG

James G. McArthur

President, CEO, Treasurer, Secretary & Director

Dr. James G. McArthur, Ph.D., serves as the President, Chief Executive Officer, Treasurer and Secretary of PepGen Inc. since January 21, 2021. He joined PepGen Inc. in January 2021. He serves as the President and Chief Executive Officer at PepGen LTD since joining the firm on February 4, 2021. He served as Venture Partner at RA Capital Management, L.P till February 3, 2021. He founded Cydan II, Inc. in 2013 and serves as its Chief Scientific Officer and President of Research and Development. He served as Founding Director of Imara, Inc. since January 2016 until April 2020. Dr. McArthur served as Chief Executive Officer of Imara Holdings Limited since October 2016. Dr. McArthur founded Imara, Inc. in 2016 and served as its Chief Executive Officer since January 2016. He served as President of Imara, Inc. He has experience in the pharmaceutical industry and has scientific background. He co-founded Vtesse, Inc. in September 2014, Tiburio and was an advisor to Kurma Ventures. Dr. McArthur co-founded Cydan Development, Inc. in 2013 and has been its President of Research & Development since October 2016. Dr. McArthur served as Chief Scientific Officer of Cydan Development, Inc. until October 2016. Dr. McArthur served as founding Chief Scientific Officer of Adheron Therapeutics, Inc. from June 2006 to September 2012, where he focused on the development of treatments for rheumatoid arthritis and fibrotic diseases and a consultant to Adheron from September 2012 to January 2015. Using a fully outsourced model of drug development, Dr. McArthur was responsible for all Synovex activities. He was an entrepreneur in residence at HealthCare Ventures from 2005 to 2006. Previously, Dr. McArthur served as Vice President of Preclinical Development for Phylogix Inc. From 2002 to 2005, he served as the Vice President of Research for Phylogix, Inc. From 1996 to 2002, Dr. McArthur held a variety of positions at Cell Genesys Inc. including Acting Vice President of Research and Principal Scientist. Dr. McArthur served as the Acting Head of Research and Principal Scientist at Cell Genesys Inc. where he oversaw a department of 50 researchers and served on therapeutics for the treatment of hemophilia, vascular occlusive disease, colon and lung cancer. Dr. McArthur served as a Senior Scientist at Somatix Therapy. Dr. McArthur began his career in gene therapy at Somatix Therapy Corp., where he held various positions from 1994 to 1996. He served as Non-Executive Director of Nightstar Therapeutics Limited until June 07, 2019. He serves as a Director of NightstaRx Limited since November 2016. Dr. McArthur serves as a Member of the Board of Directors and Scientific Advisory Board of the Friedreich's Ataxia Research Alliance (FARA). He has consulted for venture capital groups and biotechnology companies in the areas of diabetes, thrombocytopenia, hematopoiesis and muscular dystrophy with industry experience in creating and building biotechnology companies. Dr. McArthur has extensively published and patented in the areas of gene therapy and rare diseases. He is the author of over 25 papers and inventor on 13 patents encompassing work in the areas of virology, immunology, genetic diseases, vascular biology and oncology. He served on board of T-Cure Biosciences Inc, a biotechnology company, from April 2020 to September 2020. He was a postdoctoral fellow at the Massachusetts Institute of Technology in Cambridge and the University of California, Berkeley. Dr. McArthur received his BSc in biochemistry and Ph.D. in molecular oncology and Biochemistry from McGill University in Montreal.

Positions